Agreement with Selagine, Inc. supports the development of an investigational pooled plasma biologic platform intended to move beyond individualized compounded serum tearsCHICAGO, June 9,...
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham
- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma
- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers
GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading advanced air mobility (“AAM”) technology platform company, today announced its unaudited financial results for the first quarter ended March 31, 2026.
SINGAPORE, June 9, 2026 /PRNewswire/ -- Xnergy Autonomous Power Technologies (Xnergy), a Singapore-headquartered leader in high-power wireless charging for autonomous mobility, today announced that...
/Not for distribution to U.S. news wire services or dissemination in the United States./TORONTO, June 8, 2026 /CNW/ - Apotex Health Corp. ("Apotex" or the...
Three certificates issued by Bureau Veritas support application in SOLAS-regulated marine environments across global, EU-flagged, and UK-flagged vessels.MINNETONKA, Minn., June 9, 2026 /PRNewswire/ --...